Out-Of-Hospital Cardiac Arrest (OHCA)
Conditions
Brief summary
This single-center proof of concept study aims to assess the efficacy of a blood pressure strategy targeting person- and time-specific cerebral blood flow compared with standard-of-care using neuron-specific enolase as a quantitative biomarker of brain injury. Our central hypothesis is that an individualized blood pressure strategy targeting cerebral perfusion will reduce the extent of brain injury as indicated by changes in levels of neuron-specific enolase from baseline at 72 hours. To test this hypothesis, we will recruit 49 patients to an individualized blood pressure management strategy targeting cerebral blood flow, where optimal blood pressure will be serially calculated by the ICM+ brain monitoring software (Cambridge, UK) using inputs from transcranial Doppler ultrasound and near-infrared spectroscopy.
Interventions
OTHERIndividualized blood pressure strategy
An individualized blood pressure strategy targeting cerebral blood flow, serially guided by near-infrared spectroscopy and transcranial Doppler ultrasound. Assessments are performed on admission, and at 12, 24 and 48 hours post-ROSC.
Sponsors
National University Hospital, Singapore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
1. At least 21 years of age 2. Comatose defined as not being able to obey verbal commands and no verbal response to pain after sustained ROSC.
Exclusion criteria
1. ≥ 80 years old at time of enrolment 2. Pregnant patients 3. Limitations of care or life support therapy withdrawn within 24 hours of admission
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in neuron-specific enolase (NSE) | 72 hours post ROSC | The mean change in concentration of NSE from baseline levels to 72 hours post-ROSC. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Peak concentration of myocardial injury biomarker - N-terminal pro b-type natriuretic peptide (NT-proBNP) | Within 72hours of ROSC | Peak concentration of myocardial injury biomarker, N-terminal pro b-type natriuretic peptide (NT-proBNP) within 72 hours of ROSC |
| Peak concentration of renal function - Creatinine | Within 72hours of ROSC | Peak concentration of renal function, Creatinine within 72 hours of ROSC |
| Peak concentration of renal injury biomarker - Proenkephalin A 119-159 (penKID) | Within 72hours of ROSC | Peak concentration of renal injury biomarker, Proenkephalin A 119-159 (penKID) within 72 hours of ROSC |
| Peak concentration of renal injury biomarker - Biologically active adrenomedullin (bio-ADM) | Within 72hours of ROSC | Peak concentration of renal injury biomarker, Biologically active adrenomedullin (bio-ADM) within 72 hours of ROSC |
| Peak concentration of renal injury biomarker - Tissue inhibitor of metalloproteinases 2 (TIMP2) | Within 72hours of ROSC | Peak concentration of renal injury biomarker, Tissue inhibitor of metalloproteinases 2 (TIMP2) within 72 hours of ROSC |
| Peak concentration of renal injury biomarker - Insulin Like Growth Factor Binding Protein 7 (IGFBP7) | Within 72hours of ROSC | Peak concentration of renal injury biomarker, Insulin Like Growth Factor Binding Protein 7 (IGFBP7) within 72 hours of ROSC |
| Peak concentration of myocardial injury biomarker - High-sensitive troponin (hsTNT) | Within 72hours of ROSC | Peak concentration of myocardial injury biomarker, High-sensitive troponin (hsTNT) within 72 hours of ROSC |
| Physical function | Through study completion, average of 12 months post OHCA | Physical function measured by the change of Duke Activity Status Index (DASI) self-reported questionnaire on hospital discharge, and at 3, 6 and 12 months post OHCA. DASI score is the sum of the questionnaire responses, score of 34 or less means moderate-to-severe complications. |
| Neurocognitive outcome - Montreal Cognitive Assessment (MOCA) | Through study completion, average of 12 months post OHCA | Neurocognitive is assessed by Montreal Cognitive Assessment (MOCA, global cognition) on hospital discharge, and at 3, 6 and 12 months post OHCA. Scores on the MOCA from zero to 30, while score of 26 and above is considered normal. |
| Neuropsychological outcome - Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | Through study completion, average of 12 months post OHCA | Neuropsychological deficits is assessed by the modified local version of Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) on hospital discharge, and at 3, 6 and 12 months post OHCA. Standard scores of 70 and above will classify as average/mild impairment, scores 55 to 69 as moderate impairment and severe impairment for scores less than 55. |
| Neuropsychological outcome- Depression, Anxiety, and Stress Scale (DASS-21) | Through study completion, average of 12 months post OHCA | Depression, Anxiety, and Stress Scale (DASS-21) is used to assess neuropsychological outcome on hospital discharge, and at 3, 6 and 12 months post OHCA. |
| Health-related quality of life | Through study completion, average of 12 months post OHCA | Health-related quality of life measured by EuroQol-5 Dimension-5 Level (EQ-5D-5L) questionnaire on hospital discharge, and at 3, 6 and 12 months post OHCA. EQ-5D-5L questionnaire consists of 5 dimensions (mobility, self care, usual activities, pain/comfort, anxiety/depression). There are 5 levels in each dimensions. The lowest level means normal which the highest level means extremely severe. |
| Neurological outcome | Through study completion, average of 12 months post OHCA | Neurological outcomes measured by Cerebral Performance Category (CPC) scale on hospital discharge, and at 3, 6 and 12 months post OHCA. The CPC purports to assess domains of functioning after cardiopulmonary resuscitation (CPR) with scores ranging from 1 (good cerebral performance/normal life) to 5 (brain death). |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory outcome - Digital neurocognitive assessment | Through study completion, average of 12 months post OHCA | Neurocognitive is assessed by digital neurocognitive assessment on hospital discharge, and at 3, 6 and 12 months post OHCA. |
Countries
Singapore
Contacts
Primary ContactShir Lynn Lim
Outcome results
None listed